Blazeman Foundation and Wake Forest Innovations Support Potential Treatment for Amyotrophic Lateral Sclerosis

Researchers at Wake Forest Baptist Medical Center are looking for ways to treat the debilitating disease, Amyotrophic Lateral Sclerosis (ALS), which is also known as Lou Gehrig’s Disease. In previous research, Wake Forest Baptist’s research group, led by Dr. Carol Milligan, found that using “heat shock” proteins to help control muscle movement in mice actually delayed the onset of ALS symptoms and extended survival times. This is big news for this potential new treatment of the progressive neurodegenerative disease.

Amyotrophic-Lateral-Sclerosis-Research

Supporting Amyotrophic Lateral Sclerosis Research

To support Milligan’s efforts to find an economic way to reproduce these heat shock proteins, Wake Forest Innovations, Wake Forest Baptist’s commercialization arm, will provide key resources and the Blazeman Foundation, a family foundation started in memory of the late Jonathan “Blazeman” Blais, will provide $200,000 in funding.

Learn more about this support of Dr. Milligan’s groundbreaking work to help treat patients with ALS.